サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1362916

In Vitro大腸がんスクリーニング検査の市場規模、シェア、動向分析レポート：検査タイプ別、地域別、セグメント別予測、2023年～2030年

In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test Type (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 129 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.11円
In Vitro大腸がんスクリーニング検査の市場規模、シェア、動向分析レポート：検査タイプ別、地域別、セグメント別予測、2023年～2030年
出版日: 2023年09月07日
発行: Grand View Research
ページ情報: 英文 129 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

In Vitro大腸がんスクリーニング検査市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のIn Vitro大腸がんスクリーニング検査市場規模は、2023年から2030年にかけてCAGR 3.02%で拡大し、2030年には11億2,000万米ドルに達すると予測されています。

結腸・直腸悪性腫瘍の増加傾向に対抗するための新規スクリーニングモデルの増加が、市場成長に影響を与える主な要因です。腫瘍M2-PK便検査やメチル化遺伝子検査など、新たに開発された遺伝子検査やバイオマーカー検査の出現は、腫瘍診断モデルの採用率を押し上げると予測されています。

大腸悪性腫瘍の罹患率の増加は、このセグメントの成長の重要な促進要因です。例えば、国立がん研究センターが2022年6月に発表したデータによると、日本では2022年に約1,019,000人の新規がん症例が発生すると予測されており、大腸がん（CRC）は推定158,200人の新規症例を占めています。同様に、Cancer Australiaが2022年8月に更新したデータによると、オーストラリアでは2022年に15,713例の新規CRC症例が診断され、男性では8,300例、女性では7,413例が診断されると予測されています。その結果、大腸悪性腫瘍の有病率の増加が大腸内視鏡検査機器の需要を促進すると予想されます。

検診を促進するための公的機関によるさまざまなイニシアチブの実施は、In Vitro CRC検診の需要にプラスの影響を与えています。例えば、Cancer.orgの報告によると、カリフォルニア州の医療機関は2020年4月と5月の間、FITキット（糞便免疫化学検査）の提供を継続し、COVID-19の大流行が始まったにもかかわらず、FITの反応率は高いままでした。さらに、欧州のがんコミュニティは、COVID-19が検診に及ぼす悪影響を評価し、対処し、緩和するためにリソースを動員しました。こうした努力は、In Vitroスクリーニング検査に対する持続的な需要に寄与しています。

さらに、市場の成長は、主要な市場参入企業による製品上市の増加によって牽引されると予想されます。これらの製品発売は、技術的に高度で革新的な製品へのアクセスを提供することを目的としています。例えば、Pillar Biosciences, Inc.は、2021年7月にCRC検出用のONCO/Reveal Dx Lung &Colon Cancer Assay（O/RDx-LCCA）のFDA承認を取得しました。

In Vitro大腸がんスクリーニング検査市場レポートハイライト：

  • 検査タイプ別では、便潜血検査セグメントが2022年に市場で最大のシェアを占めました。
  • FOB検査セグメントの中では、免疫FOB ELISA検査が2022年に大きなシェアを占めました。免疫検査は従来のグアイアックFOB便検査よりも精度が高いからです。
  • バイオマーカー検査は、非侵襲的なスクリーニング方法の出現により、予測期間中に収益シェアを拡大すると予想されます。
  • 腫瘍M2-PK便検査は、ScheBo Biotech AGによるScheBo腫瘍M2-PK便検査などの最近の製品イントロダクションより、2022年に最大の収益を上げました。
  • CRCのDNAスクリーニング検査では、先進的な遺伝子スクリーニング検査であるパネルDNA検査が台頭しており、最大の収益シェアに寄与しています。
  • 北米は2022年に市場の最大シェアを占めたが、これはメラノーマ検出のための臨床ワークフローにおけるこれらの製品の高い採用率に起因しています。
  • 同市場で事業を展開する主要企業には、Abbott Laboratories社、Quest Diagnostics社、Siemens AG社、Randox Laboratories社、Kyowa Medex社、GeneNews社などが含まれ、同市場でより高いシェアを獲得するため、常に製品の発売と地理的拡大に注力しています。
  • 2022年12月、米国のGuardant Health, Inc.は、ECLIPSE研究から良好な結果が得られたと報告しました。この大規模な研究は2万人以上の患者を対象としており、平均的なリスクを持つ成人の大腸がん（CRC）検出におけるガーダント・ヘルス社の血液検査の有効性を評価することを目的としていました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 業界分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19感染症の影響分析

第4章 検査タイプのビジネス分析

  • In Vitro大腸がんスクリーニング検査市場：検査タイプの変動分析
  • 便潜血検査
    • 便潜血検査市場、2018年～2030年
    • グアヤック FOB便検査
    • 免疫FOB凝集試験
    • ラテラルフロー免疫FOB試験
    • 免疫FOB ELISA検査
  • バイオマーカー検査
    • バイオマーカー検査市場、2018～2030年
    • 腫瘍M2-PK便検査
    • トランスフェリンアッセイ
    • 免疫FOB ELISA検査
  • CRC DNAスクリーニング検査
    • CRC DNAスクリーニング検査市場、2018～2030年
    • メチル化遺伝子検査
    • パネルDNA検査

第5章 地域のビジネス分析

  • In Vitro大腸がんスクリーニング検査市場シェア：地域別、2022年および2030年
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 競合情勢

  • 企業の分類
  • 戦略マッピング
  • 企業の市場シェア分析、2022年
  • 企業プロファイル・一覧表
    • Abbott
    • Beckman Coulter Inc
    • Eiken Chemical Co., Ltd.
    • Epigenomics
    • Sysmex Corporation
    • Siemens Healthcare GmbH
    • Quest Diagnostics Incorporated
    • OncoCyte Corporation
    • Merck KGaA
    • Immunostics Inc.
    • Kyowa Kirin Co. Ltd.
    • Randox Laboratories Ltd.
    • R-Biopharm AG
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global In-vitro Colorectal Cancer Screening Tests Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 5 North America In-vitro Colorectal Cancer Screening Tests Market, By Country, 2018 - 2030 (USD Million)
  • Table 6 North America In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 8 Canada America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 9 Europe America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 10 Europe America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 11 UK America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 12 Germany America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 13 France America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 14 Italy America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 15 Spain America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 16 Sweden America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 17 Norway America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 18 Russia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
  • Table 19 Denmark America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 20 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
  • Table 21 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 22 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 23 Japan America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 24 China America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 25 India America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 26 Australia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 27 Thailand America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 28 South Korea America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 29 Latin America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 30 Latin America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 31 Brazil America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 32 Mexico America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 33 Argentina America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 34 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
  • Table 35 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 36 South Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 37 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 38 UAE In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
  • Table 39 UAE In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)
  • Table 40 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 In-vitro Colorectal Cancer Screening Tests Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 In-vitro colorectal cancer screening tests market: Test type outlook and key takeaways
  • Fig. 15 In-vitro colorectal cancer screening tests market: Test type movement analysis & market share 2022 & 2030
  • Fig. 16 Global fecal occult blood tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Global guaiac FOB stool tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Immuno-FOB agglutination tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Lateral flow immuno-FOB tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Immuno-FOB ELISA tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Global biomarker tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Tumor M2-PK stool tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Transferrin assays market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Global CRC DNA screening tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Methylated gene testing market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Panel DNA tests market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Regional Marketplace: Key Takeaways
  • Fig. 28 Regional Outlook, 2022 & 2030
  • Fig. 29 Regional Market Dashboard
  • Fig. 30 Regional Market Place: Key Takeaways
  • Fig. 31 North America, SWOT Analysis
  • Fig. 32 Europe, SWOT Analysis
  • Fig. 33 Asia Pacific, SWOT Analysis
  • Fig. 34 Latin America, SWOT Analysis
  • Fig. 35 MEA, SWOT Analysis
  • Fig. 36 North America
  • Fig. 37 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 U.S. Key Country Dynamics
  • Fig. 39 U.S. America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 40 Canada Key Country Dynamics
  • Fig. 41 Canada America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 42 Europe America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 43 UK Key Country Dynamics
  • Fig. 44 UK America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 45 Germany Key Country Dynamics
  • Fig. 46 Germany America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 47 France Key Country Dynamics
  • Fig. 48 France America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 49 Italy Key Country Dynamics
  • Fig. 50 Italy America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 51 Spain Key Country Dynamics
  • Fig. 52 Spain America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 53 Sweden Key Country Dynamics
  • Fig. 54 Sweden America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 55 Norway Key Country Dynamics
  • Fig. 56 Norway America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 57 Denmark Key Country Dynamics
  • Fig. 58 Denmark America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 59 Russia Key Country Dynamics
  • Fig. 60 Russia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 61 Netherlands Key Country Dynamics
  • Fig. 62 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 63 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 64 Japan Key Country Dynamics
  • Fig. 65 Japan America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 66 China Key Country Dynamics
  • Fig. 67 China America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 68 India Key Country Dynamics
  • Fig. 69 India America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 70 Australia Key Country Dynamics
  • Fig. 71 Australia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand Key Country Dynamics
  • Fig. 73 Thailand America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea Key Country Dynamics
  • Fig. 75 South Korea America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 76 Latin America America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 77 Brazil Key Country Dynamics
  • Fig. 78 Brazil America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 79 Mexico Key Country Dynamics
  • Fig. 80 Mexico America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina Key Country Dynamics
  • Fig. 82 Argentina America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa Key Country Dynamics
  • Fig. 85 South Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia Key Country Dynamics
  • Fig. 87 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 88 UAE Key Country Dynamics
  • Fig. 89 UAE America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait Key Country Dynamics
  • Fig. 91 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • Fig. 92 Strategy Mapping
目次
Product Code: 978-1-68038-438-3

In-vitro Colorectal Cancer Screening Tests Market Growth & Trends:

The global in-vitro colorectal cancer screening tests market size is expected to reach USD 1.12 billion by 2030, expandingat a CAGR of 3.02% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising number of novel screening models to combat the increasing incidences of colon and rectal malignancy cases is the major factor influencing the market growth. The emergence of newly developed genetic and biomarker tests such as tumor M2-PK stool tests and methylated gene testing is anticipated to drive the adoption rate of tumor diagnostic models.

The increasing incidence of colorectal malignancy is a significant driver for the growth of the segment. For example, according to data released by the National Cancer Center Japan in June 2022, it was projected that there would be approximately 1,019,000 new cases of cancer in Japan in 2022, with Colorectal Cancer (CRC) accounting for an estimated 158,200 new cases. Similarly, data updated by Cancer Australia in August 2022 indicated that 15,713 new cases of CRC were expected to be diagnosed in Australia in 2022, with 8,300 cases among males and 7,413 cases among females. As a result, the increasing prevalence of colorectal malignance is anticipated to drive the demand for colonoscopy devices.

The implementation of various initiatives by public organizations to promote screening has positively impacted the demand for in-vitro CRC screenings. For instance, according to reports from Cancer.org, healthcare systems in California continued to provide FIT kits (fecal immunochemical tests) during the months of April and May 2020, and the response rates for FIT remained high despite the onset of the COVID-19 pandemic. Additionally, the European Cancer community has mobilized its resources to evaluate, address, and mitigate the adverse effects of COVID-19 on screening. These efforts have contributed to the sustained demand for in-vitro screening tests.

Furthermore, market growth is expected to be driven by the increasing number of product launches by major market players. These product launches are aimed at providing access to technologically advanced and innovative products. For instance, Pillar Biosciences, Inc. received FDA approval for the ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) in July 2021 for the detection of CRC.

In-vitro Colorectal Cancer Screening Tests Market Report Highlights:

  • Based on test type, fecal occult blood testing segment held the largest share of the market in 2022 due to their wider usage and easy applicability by large customer base
  • Among FOB test segment, immuno-FOB ELISA test held a significant share in 2022, as immunological testing offers more accuracy than conventional guaiac FOB stool test
  • Biomarker tests are expected to gain revenue share over the forecast period due to the emergence of noninvasive screening procedures
  • Tumor M2-PK stool test generated maximum revenue in 2022 due to recent product introduction such as ScheBo Tumor M2-PK Stool Test by ScheBo Biotech AG
  • In CRC DNA screening test vertical, panel DNA tests are gaining ground as these are advanced genetic screening tests, thus contributing the maximum revenue share
  • North America held the largest share of the market in 2022, which can be attributed to high adoption rate of these products in clinical workflow for detection of melanoma
  • Key players operating in the market include Abbott Laboratories; Quest Diagnostics; Siemens AG; Randox Laboratories; Kyowa Medex; and GeneNews and are constantly focusing on product launches and geographical expansion to gain higher share in the market
  • In December 2022, Guardant Health, Inc., a company based in the United States, reported positive findings from the ECLIPSE study. This extensive study involved more than 20,000 patients and aimed to assess the effectiveness of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Test type segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Test Type Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing incidence of colon and rectal cancers
      • 3.2.1.2. Growing accuracy of colorectal cancer screening by use of genetic testing
      • 3.2.1.3. Presence of a number of colorectal cancer screening products in pipeline
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Pending investigational evidence for certain genetic screening tests
      • 3.2.2.2. Difficulty to undertake CRC screening tests to encompass the entire
      • 3.2.2.3. Lack of cancer screening guideless in Asia Pacific region
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Test Type Business Analysis

  • 4.1. In-vitro Colorectal Cancer Screening Tests Market: Test Type Movement Analysis
  • 4.2. Fecal Occult Blood Tests
    • 4.2.1. Fecal Occult Blood Tests Market, 2018 - 2030 (USD Million)
    • 4.2.2. Guaiac FOB Stool Test
      • 4.2.2.1. Guaiac FOB Stool Test Market, 2018 - 2030 (USD Million)
    • 4.2.3. Immuno-FOB Agglutination Test
      • 4.2.3.1. Immuno-FOB Agglutination Test Market, 2018 - 2030 (USD Million)
    • 4.2.4. Lateral Flow Immuno-FOB Test
      • 4.2.4.1. Lateral Flow Immuno-FOB Test Market, 2018 - 2030 (USD Million)
    • 4.2.5. Immuno-FOB ELISA Test
      • 4.2.5.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
  • 4.3. Biomarker Tests Market
    • 4.3.1. Biomarker Tests Market, 2018 - 2030 (USD Million)
    • 4.3.2. Tumor M2-PK Stool Test
      • 4.3.2.1. Tumor M2-PK Stool Test Market, 2018 - 2030 (USD Million)
    • 4.3.3. Transferrin Assays
      • 4.3.3.1. Transferrin Assays Market, 2018 - 2030 (USD Million)
    • 4.3.4. Immuno-FOB ELISA Test
      • 4.3.4.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
  • 4.4. CRC DNA Screening Tests
    • 4.4.1. CRC DNA Screening Tests Market, 2018 - 2030 (USD Million)
    • 4.4.2. Methylated Gene Testing
      • 4.4.2.1. Methylated Gene Testing Market, 2018 - 2030 (USD Million)
    • 4.4.3. Panel DNA Tests
      • 4.4.3.1. Panel DNA Tests Market, 2018 - 2030 (USD Million)

Chapter 5. Regional Business Analysis

  • 5.1. In-vitro Colorectal Cancer Screening Tests Market Share By Region, 2022 & 2030
  • 5.2. North America
    • 5.2.1. SWOT Analysis
    • 5.2.2. North America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.2.3. U.S.
      • 5.2.3.1. Key Country Dynamics
      • 5.2.3.2. Target Disease Prevalence
      • 5.2.3.3. Competitive Scenario
      • 5.2.3.4. Regulatory Framework
      • 5.2.3.5. U.S. In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.2.4. Canada
      • 5.2.4.1. Key Country Dynamics
      • 5.2.4.2. Target Disease Prevalence
      • 5.2.4.3. Competitive Scenario
      • 5.2.4.4. Regulatory Framework
      • 5.2.4.5. Canada In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.3. Europe
    • 5.3.1. SWOT Analysis
    • 5.3.2. Europe In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.3. UK
      • 5.3.3.1. Key Country Dynamics
      • 5.3.3.2. Target Disease Prevalence
      • 5.3.3.3. Competitive Scenario
      • 5.3.3.4. Regulatory Framework
      • 5.3.3.5. UK In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.4. Germany
      • 5.3.4.1. Key Country Dynamics
      • 5.3.4.2. Target Disease Prevalence
      • 5.3.4.3. Competitive Scenario
      • 5.3.4.4. Regulatory Framework
      • 5.3.4.5. Germany In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.5. France
      • 5.3.5.1. Key Country Dynamics
      • 5.3.5.2. Target Disease Prevalence
      • 5.3.5.3. Competitive Scenario
      • 5.3.5.4. Regulatory Framework
      • 5.3.5.5. France In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.6. Italy
      • 5.3.6.1. Key Country Dynamics
      • 5.3.6.2. Target Disease Prevalence
      • 5.3.6.3. Competitive Scenario
      • 5.3.6.4. Regulatory Framework
      • 5.3.6.5. Italy In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.7. Spain
      • 5.3.7.1. Key Country Dynamics
      • 5.3.7.2. Target Disease Prevalence
      • 5.3.7.3. Competitive Scenario
      • 5.3.7.4. Regulatory Framework
      • 5.3.7.5. Spain In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.8. Sweden
      • 5.3.8.1. Key Country Dynamics
      • 5.3.8.2. Target Disease Prevalence
      • 5.3.8.3. Competitive Scenario
      • 5.3.8.4. Regulatory Framework
      • 5.3.8.5. Sweden In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.9. Norway
      • 5.3.9.1. Key Country Dynamics
      • 5.3.9.2. Target Disease Prevalence
      • 5.3.9.3. Competitive Scenario
      • 5.3.9.4. Regulatory Framework
      • 5.3.9.5. Norway In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.10. Denmark
      • 5.3.10.1. Key Country Dynamics
      • 5.3.10.2. Target Disease Prevalence
      • 5.3.10.3. Competitive Scenario
      • 5.3.10.4. Regulatory Framework
      • 5.3.10.5. Denmark In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.11. Russia
      • 5.3.11.1. Key Country Dynamics
      • 5.3.11.2. Target Disease Prevalence
      • 5.3.11.3. Competitive Scenario
      • 5.3.11.4. Regulatory Framework
      • 5.3.11.5. Russia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.3.12. Netherlands
      • 5.3.12.1. Key Country Dynamics
      • 5.3.12.2. Target Disease Prevalence
      • 5.3.12.3. Competitive Scenario
      • 5.3.12.4. Regulatory Framework
      • 5.3.12.5. Netherlands In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.4. Asia Pacific
    • 5.4.1. SWOT Analysis
    • 5.4.2. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.3. Japan
      • 5.4.3.1. Key Country Dynamics
      • 5.4.3.2. Target Disease Prevalence
      • 5.4.3.3. Competitive Scenario
      • 5.4.3.4. Regulatory Framework
      • 5.4.3.5. Japan In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.4. China
      • 5.4.4.1. Key Country Dynamics
      • 5.4.4.2. Target Disease Prevalence
      • 5.4.4.3. Competitive Scenario
      • 5.4.4.4. Regulatory Framework
      • 5.4.4.5. China In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.5. India
      • 5.4.5.1. Key Country Dynamics
      • 5.4.5.2. Target Disease Prevalence
      • 5.4.5.3. Competitive Scenario
      • 5.4.5.4. Regulatory Framework
      • 5.4.5.5. India In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.6. Australia
      • 5.4.6.1. Key Country Dynamics
      • 5.4.6.2. Target Disease Prevalence
      • 5.4.6.3. Competitive Scenario
      • 5.4.6.4. Regulatory Framework
      • 5.4.6.5. Australia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.7. Thailand
      • 5.4.7.1. Key Country Dynamics
      • 5.4.7.2. Target Disease Prevalence
      • 5.4.7.3. Competitive Scenario
      • 5.4.7.4. Regulatory Framework
      • 5.4.7.5. Thailand In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.4.8. South Korea
      • 5.4.8.1. Key Country Dynamics
      • 5.4.8.2. Target Disease Prevalence
      • 5.4.8.3. Competitive Scenario
      • 5.4.8.4. Regulatory Framework
      • 5.4.8.5. South Korea In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.5. Latin America
    • 5.5.1. SWOT Analysis
    • 5.5.2. Latin America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.3. Brazil
      • 5.5.3.1. Key Country Dynamics
      • 5.5.3.2. Target Disease Prevalence
      • 5.5.3.3. Competitive Scenario
      • 5.5.3.4. Regulatory Framework
      • 5.5.3.5. Brazil In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.4. Mexico
      • 5.5.4.1. Key Country Dynamics
      • 5.5.4.2. Target Disease Prevalence
      • 5.5.4.3. Competitive Scenario
      • 5.5.4.4. Regulatory Framework
      • 5.5.4.5. Mexico In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.5.5. Argentina
      • 5.5.5.1. Key Country Dynamics
      • 5.5.5.2. Target Disease Prevalence
      • 5.5.5.3. Competitive Scenario
      • 5.5.5.4. Regulatory Framework
      • 5.5.5.5. Argentina In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
  • 5.6. MEA
    • 5.6.1. SWOT Analysis
    • 5.6.2. MEA In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.3. South Africa
      • 5.6.3.1. Key Country Dynamics
      • 5.6.3.2. Target Disease Prevalence
      • 5.6.3.3. Competitive Scenario
      • 5.6.3.4. Regulatory Framework
      • 5.6.3.5. South Africa In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.4. Saudi Arabia
      • 5.6.4.1. Key Country Dynamics
      • 5.6.4.2. Target Disease Prevalence
      • 5.6.4.3. Competitive Scenario
      • 5.6.4.4. Regulatory Framework
      • 5.6.4.5. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.5. UAE
      • 5.6.5.1. Key Country Dynamics
      • 5.6.5.2. Target Disease Prevalence
      • 5.6.5.3. Competitive Scenario
      • 5.6.5.4. Regulatory Framework
      • 5.6.5.5. UAE In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
    • 5.6.6. Kuwait
      • 5.6.6.1. Key Country Dynamics
      • 5.6.6.2. Target Disease Prevalence
      • 5.6.6.3. Competitive Scenario
      • 5.6.6.4. Regulatory Framework
      • 5.6.6.5. Kuwait In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Company Categorization
  • 6.2. Strategy Mapping
  • 6.3. Company Market Share Analysis, 2022
  • 6.4. Company Profiles/Listing
    • 6.4.1. Abbott
      • 6.4.1.1. Overview
      • 6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.1.3. Product Benchmarking
      • 6.4.1.4. Strategic Initiatives
    • 6.4.2. Beckman Coulter Inc
      • 6.4.2.1. Overview
      • 6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.2.3. Product Benchmarking
      • 6.4.2.4. Strategic Initiatives
    • 6.4.3. Eiken Chemical Co., Ltd.
      • 6.4.3.1. Overview
      • 6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.3.3. Product Benchmarking
      • 6.4.3.4. Strategic Initiatives
    • 6.4.4. Epigenomics
      • 6.4.4.1. Overview
      • 6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.4.3. Product Benchmarking
      • 6.4.4.4. Strategic Initiatives
    • 6.4.5. Sysmex Corporation
      • 6.4.5.1. Overview
      • 6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.5.3. Product Benchmarking
      • 6.4.5.4. Strategic Initiatives
    • 6.4.6. Siemens Healthcare GmbH
      • 6.4.6.1. Overview
      • 6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.6.3. Product Benchmarking
      • 6.4.6.4. Strategic Initiatives
    • 6.4.7. Quest Diagnostics Incorporated
      • 6.4.7.1. Overview
      • 6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.7.3. Product Benchmarking
      • 6.4.7.4. Strategic Initiatives
    • 6.4.8. OncoCyte Corporation
      • 6.4.8.1. Overview
      • 6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.8.3. Product Benchmarking
      • 6.4.8.4. Strategic Initiatives
    • 6.4.9. Merck KGaA
      • 6.4.9.1. Overview
      • 6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.9.3. Product Benchmarking
      • 6.4.9.4. Strategic Initiatives
    • 6.4.10. Immunostics Inc.
      • 6.4.10.1. Overview
      • 6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.10.3. Product Benchmarking
      • 6.4.10.4. Strategic Initiatives
    • 6.4.11. Kyowa Kirin Co. Ltd.
      • 6.4.11.1. Overview
      • 6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.11.3. Product Benchmarking
      • 6.4.11.4. Strategic Initiatives
    • 6.4.12. Randox Laboratories Ltd.
      • 6.4.12.1. Overview
      • 6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.12.3. Product Benchmarking
      • 6.4.12.4. Strategic Initiatives
    • 6.4.13. R-Biopharm AG
      • 6.4.13.1. Overview
      • 6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 6.4.13.3. Product Benchmarking
      • 6.4.13.4. Strategic Initiatives